The anti-depressant drug Effexor has been linked to several serious side effects and complications in patients taking the medication. Some of these side effects can cause lasting harm to fetuses of pregnant patients. Many side effects can be deadly.
The antidepressant and anti-anxiety drug Effexor (venlafaxine) has been linked to serious side effects and complications that can be deadly to patients and fetuses. One such birth defect associated with Effexor use in pregnancy is a serious and potentially fatal condition affecting the heart and lungs of newborns.
Effexor and Effexor XR (the extended-release version of the drug) work to boost serotonin and norepinephrine levels in the brain by blocking the neurotransmitters’ reabsorption, thereby attempting to increase positive feelings along with alertness and energy. But Effexor can worsen depression and lead to a heightened risk of suicidal thoughts and behaviors.
The use of antidepressants has been linked to an increased risk of miscarriage, according to a study published in the Canadian Medical Association Journal (CMAJ) in 2010.
University of Montreal and the CHU Sainte-Justine Mother and Child University Hospital researchers reviewed data collected by the Quebec Pregnancy Registry from 1998 to 2003. The review covered information about 70,000 women between the ages of 15 to 45.
The evaluation included over 5,000 women who had experienced miscarriages up to 20 weeks into the pregnancy and another 51,000 women who did not have miscarriages. Of those women who miscarried, about 5.5 percent (or 284) had taken antidepressants during their pregnancy.
Overall, the study found a 68 percent increased risk of miscarriage in women who used antidepressants, such as Effexor, during pregnancy compared to those women who never used antidepressants.
A miscarriage is the unexpected loss of a fetus occurring before the 20th week of pregnancy, or gestation. If the loss of a fetus occurs after the 20th week, it is referred to as a stillbirth rather than a miscarriage. The majority of miscarriages happen very early in a pregnancy, sometimes before a woman even knows she is pregnant.
The risk of miscarriage is also higher in women who are older, typically over 30, even greater for those between 35 and 40 years of age, and highest after 40 and in women who have previously had a pregnancy that ended in miscarriage.
Vaginal spotting or bleeding may be a symptom of miscarriage or a sign that a miscarriage will occur. However, some women have bleeding in early pregnancy and don’t miscarry. Any bleeding that occurs during a pregnancy should be evaluated by a health care professional.
When a miscarriage happens early in a pregnancy, treatment is not typically needed.
If tissue remains in the uterus, a procedure called a dilatation and curettage (D&C) may be required to remove it and prevent serious infection and further, possibly life-threatening, complications . This surgical procedure involves dilating the opening to the uterus (the cervix) and inserting a small suction tube that scrapes the lining of the uterine walls and empties any pregnancy-related contents.
The FDA warned consumers about the link between the use of selective serotonin-reuptake inhibitor (SSRI) antidepressants during pregnancy and persistent pulmonary hypertension of the newborn (PPHN). PPHN is a serious, sometimes fatal, condition affecting an infant’s heart and lungs.
The FDA’s warning came in late 2011, over five years after the publication of one case-controlled study in The New England Journal of Medicine (NEJM) that determined a risk of PPHN in infantswhose mothers used SSRIs during pregnancy, especially during the third trimester.
Women who take an SNRI, such as Effexor, after the 20th week of pregnancy have also been found to have a six-fold increased risk of having a baby with PPHN.
PPHN damages a newborn’s heart and lungs, making it difficult for the baby to adapt to the environment outside the womb. The condition is rarely detected in utero, and in about 10 to 20 percent of cases, the infant will not survive.
Persistent pulmonary hypertension of the newborn is a severe pulmonary disorder that affects approximately one in every 500 live births. The condition is characterized by the failure of the normal circulatory transition that happens after birth, resulting in shunting (diversion) of blood away from the lungs.
While it is possible for some infants with PPHN to die from the disorder, seven to 20 percent of those who survive will develop long-term complications of the disorder.
Pulmonary hypertension is high blood pressure in the arteries of the lungs. It also affects the right side of the heart, causing it to work harder than normal to pump oxygen-rich blood throughout the body.
Unlike adults with pulmonary hypertension, a diagnosis of PPHN is confirmed in newborns regardless of the pressure on the pulmonary arteries, as long as the condition is accompanied by right-to-left shunting without the presence of congenital heart disease.
Blood is pumped through the lungs by the right side of the heart where it collects oxygen. The oxygen-saturated blood then returns to the left side of the heart, where it is pumped to the rest of the body. When the small arteries in the lung narrow, they are unable to carry enough blood. Pressure then builds up, resulting in pulmonary hypertension.
This results in the heart over-working itself to force the blood through the vessels fighting against the building pressure. Over time, this extra work causes the heart to enlarge, resulting in right-sided heart failure.
In PPHN, hypoxemia, or an abnormally low level of oxygen in the blood, is a secondary condition.
Frequently changing oxygen levels are often a part of persistent pulmonary hypertension of the newborn. Abnormally rapid breathing (tachypnea) can lead to a severe state of oxygen deprivation in the body (asphyxia). This serious symptom of PPHN can result in the loss of consciousness or death.
There is no cure for pulmonary hypertension, and likewise, persistent pulmonary hypertension of the newborn (PPHN).
The primary goal of treatment is to control the patient’s symptoms and prevent any more lung damage from occurring. This can be done by maintaining adequate systemic blood pressure, thereby decreasing pulmonary (affecting the lungs) resistance and ensuring that oxygen reaches the body’s tissues.
Effexor’s drug label contains a long list of warnings and precautions linking the antidepressant drug to several other serious side effects and complications.
Like most other antidepressant medications, Effexor has been associated with the worsening of depression and the emergence of suicidal thoughts and/or behaviors, or unusual changes in behavior.
The labeling warns that this “long-standing concern” of antidepressant use leading to an increased risk of suicide in patients, is especially apparent in the “early phases of treatment.” Children, adolescents and young adults who suffer from major depressive disorder (MDD) and other psychiatric disorders, are at an even greater risk of suicide than their counterparts over age 24, and especially those aged 65 and older, who contrarily show a reduction in suicidal risk with the use of antidepressants compared to placebo-controlled groups.
The FDA alerted health care professionals to a link between venlafaxine (the active ingredient in Effexor) and a potentially life-threatening condition called serotonin syndrome. The risk of a patient developing this serious and sometime fatal condition is heightened in individuals taking Effexor along with other serotonergic drugs, such as triptans, tricyclic antidepressants, amphetamines and St. John’s Wort, and drugs that impair metabolism of serotonin, such as MAOIs, including those used to treat psychiatric disorders and others.
Results of controlled trials found dose-related increases in systolic and diastolic blood pressure. These clinical trials also found a link between Effexor use and cases of sustained high blood pressure. Reports have indicated that some cases of elevated blood pressure have required immediate treatment in patients taking Effexor.
Some children taking Effexor experienced an average change in body weight or incidence of weight loss equal to 3.5 percent or more in placebo-controlled pediatric studies. This weight loss was not limited to patients experiencing anorexia (an eating disorder that results in significant weight loss) as a result of treatment with the antidepressant drug.
The difference between observed weight gain and expected weight gain was larger for children younger than 12 years of age compared with adolescents aged 12 and older.
In a six-month clinical study, both children and adolescents had height increases that were also less than expected when compared with their peers.
Decreased appetite, or treatment-emergent anorexia, was observed more frequently in pediatric patients treated with Effexor versus those treated with placebos in a premarketing evaluation.
Effexor use has been associated with interstitial lung disease and eosinophilic pneumonia in rare instances, according to drug labeling for the antidepressant medication. Interstitial lung disease is the name for a large group of diseases that can inflame or scar the lungs, resulting in a lack of oxygen. Scarring is permanent.
Eosinophilic pneumonia is a disease in which eosinophils, a type of white blood cell, accumulate in the lungs, and usually in the bloodstream. These cells invade tiny air sacs (alveoli) in the lungs, despite the absence of infection, and make breathing difficult.
Discontinuation of Effexor should be considered for patients taking the antidepressant medication when they develop shortness of breath, cough or chest discomfort associated with interstitial lung disease or eosinophilic pneumonia.
Another concern for Effexor patients is discontinuation syndrome, which can occur when the medicine is stopped suddenly, the dose is decreased too quickly or when a dose is missed.
To avoid discontinuation syndrome, some doctors switch their patients to SSRIs, which do not have as many withdrawal symptoms, before weaning them off of antidepressants altogether.
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(888) 645-1617